Publications by authors named "Akane Miura"

Article Synopsis
  • - Reports indicate that IgA nephropathy (IgAN), a kidney disease, can worsen or appear after starting TNF-α inhibitor (TNFi) therapy, particularly for Crohn's disease (CD), with unclear causes.
  • - Three patients developed kidney issues 2 to 6 years after beginning TNFi treatment, with biopsies confirming IgAN in two cases and IgAN with acute tubulointerstitial nephritis in one.
  • - All patients improved with additional corticosteroids and tonsillectomy while continuing TNFi therapy, highlighting a potential link between TNFi therapy for CD and increased risk of IgAN flare-ups.
View Article and Find Full Text PDF

Stem cell gene therapy using the MFGS-gp91 retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells.

View Article and Find Full Text PDF

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection.

View Article and Find Full Text PDF

Two patients with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (ADA-SCID) received stem cell-based gene therapy (SCGT) using GCsapM-ADA retroviral vectors without preconditioning in 2003 and 2004. The first patient (Pt1) was treated at 4.7 years old, and the second patient (Pt2), who had previously received T cell gene therapy (TCGT), was treated at 13 years old.

View Article and Find Full Text PDF

Protein phosphatase 2A (PP2A) is a conserved essential enzyme that is implicated as a tumor suppressor based on its central role in phosphorylation-dependent signaling pathways. Protein phosphatase methyl esterase (PME-1) catalyzes specifically the demethylation of the C-terminal Leu309 residue of PP2A catalytic subunit (PP2Ac). It has been shown that PME-1 affects the activity of PP2A by demethylating PP2Ac, but also by directly binding to the phosphatase active site, suggesting loss of PME-1 in cells would enhance PP2A activity.

View Article and Find Full Text PDF

Fumarate reductase (FRD) is an enzyme that reduces fumarate to succinate. In many organisms, it is bound to the membrane and uses electron donors such as quinol. In this study, an FRD from a thermophilic chemolithoautotrophic bacterium, Hydrogenobacter thermophilus TK-6, was purified and characterized.

View Article and Find Full Text PDF